Clinical Trial Update: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating disitamab vedotin in combination therapy for locally advanced or metastatic non-small cell lung cancer with HER2/ERBB2 altera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Disitamab Vedotin (RC48) (disitamab vedotin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors | Phase 2 | Status: UNKNOWN